

Anaxsys Announces an Independent Pilot Swiss Study in Colonoscopy Recommends the use of respiR8™ Continuous Respiratory Rate Counter

Breath monitoring with respiR8 is a practical and accurate method of measuring ventilation for patients undergoing endoscopic procedures under sedation

Send, UK, November 12, 2013 - Anaxsys Ltd, the medical device company developing innovative respiratory devices, today announced that an independent Swiss study ‘ Breath monitoring with a new Respiratory Rate Monitoring Device during Colonoscopy : A pilot study’ recommends the use of **respiR8™** continuous respiratory rate counter in colonoscopy procedures. **respiR8™**, which monitors respiratory rates in post-operative, trauma and emergency procedure patients, has already received a CE Mark and is available in hospitals in the U.K. and Europe.

“Apnoea (no breathing) occurs commonly during endoscopy and operations carried out under sedation and unless the ventilation is monitored continuously can lead to hypoxemia and increase the risk of other medical complications later on, including dementia,” stated Barbara Lead, Commercial Director of Anaxsys. “ Dr Anand and Dr Heuss presented their poster at the United European Gastroenterology conference in Berlin in October 2013 and highlighted the need to monitor ventilation using **respiR8™** which may provide earlier warning of impending respiratory abnormalities which are not detected by pulse oximetry alone.”

“Using **respiR8™** healthcare professionals will be able to better monitor patient respiratory rate, which has been highlighted by the medical community as the vital sign which provides the earliest indication of patient deterioration in the post-operative period yet is the least monitored. Recent studies and publications by eminent physicians and patient safety organisationsⁱ are calling for routine continuous monitoring of respiratory rate in order to improve patient safety and help reduce the incidence of post-operative drug induced respiratory depression, post-operative cognitive impairment (dementia) and cardiac arrests.”

respiR8 is the world’s first continuous electrochemical respiratory rate counter. The device consists of a novel patented sensor that is pre-fitted into a standard oxygen mask providing a

very accurate respiratory counter for doctors, nurses and emergency healthcare professionals. The mask is connected to a small electronic monitor that captures, displays and records the patients' continuous respiratory rate. **respir8** is a reliable method for this crucial monitoring procedure in the awake or sedated patient and has the potential to dramatically improve patient safety and considerably minimize post anaesthetic risks.

Ends

About Anaxsys

Anaxsys is a medical device company that develops and markets innovative respiratory devices that meet clinical needs. Anaxsys' unique approach to identifying and meeting clinical needs has resulted in a range of novel products, based on Anaxsys' patented sensor technology, to improve patient outcomes. These product ranges are targeted at patient monitoring, screening and diagnostics in the areas of vital signs, asthma, sleep apnoea and lung cancer. Anaxsys' first product to market is respiR8, a continuous respiratory rate counter that provides an early indication of patient deterioration. For more information, visit www.anaxsys.com.

###

Contact:

Barbara lead
Director
Anaxsys Ltd
t. 01483 211011
m. +44 (0)7802 433134
barbara.lead@anaxsys.com

Destanie Clarke
DestaniePR
m. +44 (0)7753 826162
destanie@destaniepr.com

ⁱ *"No Patient Shall be Harmed by Opioid-Induced Respiratory Depression"*, apsf, Fall 2011, The Official Journal of the Anesthesia Patient Safety Foundation